Genomic Markers in Prostate Cancer


Dr. Leonard Gomella, Chair of the department of Urology and the Director of the Sidney Kimmel Cancer Center Network, was recently interviewed by Targeted Oncology about four major genomic markers used to guide treatment decisions in prostate cancer.

These four genomic markers help clinicians decide between active treatment for patients with prostate cancer or active surveillance.

The four genomic markers are described in the National Comprehensive Cancer Network (NCCN) guidelines. Dr. Gomella explains that the inclusion of the markers in the NCCN guidelines should indicate to physicians that “there is validity to using these genomic markers in helping you manage your patients with prostate cancer.”